Mostrar el registro sencillo del ítem

Artículo

dc.creatorArgüelles Arias, Federicoes
dc.creatorBermejo, Fernandoes
dc.creatorBorrás-Blasco, Joaquínes
dc.creatorDomènech, Eugenies
dc.creatorSicilia, Beatrizes
dc.creatorHuguet, José M.es
dc.creatorRamírez de Arellano, Antonioes
dc.creatorValentine, William J.es
dc.creatorHunt, Barnabyes
dc.date.accessioned2022-12-05T15:13:27Z
dc.date.available2022-12-05T15:13:27Z
dc.date.issued2022
dc.identifier.citationArgüelles Arias, F., Bermejo, F., Borrás-Blasco, J., Domènech, E., Sicilia, B., Huguet, J.M.,...,Hunt, B. (2022). Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain. Therapeutic Advances in Gastroenterology, 15, 167-12. https://doi.org/10.1177/17562848221086131.
dc.identifier.issn1756-283Xes
dc.identifier.issn1756-2848es
dc.identifier.urihttps://hdl.handle.net/11441/140175
dc.description.abstractBackground: Iron deficiency anemia (IDA) is a common complication of inflammatory bowel disease (IBD) and can result in reduced quality of life and increased healthcare costs. IDA is treated with iron supplementation, commonly with intravenous iron formulations, such as ferric carboxymaltose (FCM), and iron sucrose (IS). Methods: This study assessed the cost-effectiveness of FCM compared with IS, in terms of additional cost per additional responder in patients with IDA subsequent to IBD in the Spanish setting. An economic model was developed to assess the additional cost per additional responder, defined as normalization or an increase of ⩾2g/dl in hemoglobin levels, for FCM versus IS from a Spanish healthcare payer perspective. Efficacy inputs were taken from a randomized controlled trial comparing the two interventions (FERGIcor). Costs of treatment were calculated in 2021 Euros (EUR) using a microcosting approach and included the costs of intravenous iron, healthcare professional time, and consumables. Cost-effectiveness was assessed over one cycle of treatment, with a series of sensitivity analyses performed to test the robustness of the results. Results: FCM was more effective than IS, with 84% of patients achieving a response compared with 76%. When expressed as number needed to treat, 13 patients would need to switch treatment from IS to FCM in order to achieve one additional responder. Costs of treatment were EUR 323 with FCM compared with EUR 470 with IS, a cost saving of EUR 147 with FCM. Cost savings with FCM were driven by the reduced number of infusions required, resulting in a reduced requirement for healthcare professional time and use of consumables compared with the IS arm. Conclusion: The present analysis suggests that FCM is less costly and more effective than IS for the treatment of IDA subsequent to IBD in Spain and therefore was considered dominant.es
dc.formatapplication/pdfes
dc.format.extent12 p.es
dc.language.isoenges
dc.publisherSage Publishinges
dc.relation.ispartofTherapeutic Advances in Gastroenterology, 15, 167-12.
dc.rightsAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectCostes
dc.subjectCost-effectivenesses
dc.subjectInflammatory bowel diseasees
dc.subjectIron deficiency anemiaes
dc.titleCost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spaines
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.publisherversionhttps://journals.sagepub.com/doi/10.1177/17562848221086131es
dc.identifier.doi10.1177/17562848221086131es
dc.journaltitleTherapeutic Advances in Gastroenterologyes
dc.publication.volumen15es
dc.publication.initialPage167es
dc.publication.endPage12es

FicherosTamañoFormatoVerDescripción
Cost effectiveness.pdf146.6KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Atribución-NoComercial 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Atribución-NoComercial 4.0 Internacional